Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.46 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.46 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.46 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.46 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.46 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2752131 | 0.84 | CYP1A1 (0.52) | CYP1A2CYP3A4CYP2C9CYP2B6CYP1A1 | |
| SCHEMBL1895969 | 0.83 | APP (0.52) | DYRK1ACLK4RAB9ASMN1; SMN2MAPT | |
| SCHEMBL8876829 | 0.81 | KDM4E (0.50) | CYP1A2CYP2C9CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL2897272 | 0.78 | IDO1 (0.41) | RAB9ASMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL69540 | 0.77 | KDR (0.40) | RAB9ANFKB1NFKB2RELASMN1; SMN2 | |
| SCHEMBL4754741 | 0.75 | CYP1A1 (0.47) | DYRK1ACLK4CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2751757 | 0.75 | PDE4A (0.43) | RAB9ASMN1; SMN2MAPTTDP1ALDH1A1 | |
| SCHEMBL1900288 | 0.75 | BACE1 (0.41) | DYRK1ACYP1A2CYP1A1CYP1B1TDO2 | |
| SCHEMBL4867372 | 0.75 | MAP4K4 (0.47) | DYRK1ACYP3A4RAB9ANFKB1NFKB2 | |
| SCHEMBL2752544 | 0.74 | CA12 (0.44) | CYP1A1CYP2D6CYP1B1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038265-B1 | Human protein-tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS INC (US) | 2015-03-18 | — | — | EP | claimed |
| US-20130023542-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-01-24 | — | — | US | claimed |
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | claimed |
| CN-101506180-A | Human protein tyrosine phosphatase inhibitors and methods of use | PROCTER & GAMBLE (US) | 2009-08-12 | — | — | CN | claimed |
| EP-2038265-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2008002570-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | claimed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-20200207730-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-07-02 | — | — | US | disclosed |
| US-20200108080-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-04-09 | — | — | US | disclosed |
| CN-102365023-A | Method of treating vascular leak syndrome | AKEBIA THERAPEUTICS INC | 2012-02-29 | — | — | CN | disclosed |
| US-8106078-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | WARNER CHILCOTT COMPANY, LLC (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | disclosed |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2011-09-01 | — | — | US | disclosed |
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | disclosed |
| CN-101506180-A | Human protein tyrosine phosphatase inhibitors and methods of use | PROCTER & GAMBLE (US) | 2009-08-12 | — | — | CN | disclosed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200108080-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP3 | DYRK1A 3838/4885CLK4 696/4885CYP1A2 4763/4885 |
| US-20200207730-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | DYRK1A 3997/4885CLK4 3560/4885CYP1A2 4581/4885 |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | DYRK1A 1046/4885CLK4 2819/4885CYP1A2 4861/4885 |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | DYRK1A 4095/4885CLK4 540/4885CYP1A2 4824/4885 |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | DYRK1A 3997/4885CLK4 3560/4885CYP1A2 4581/4885 |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | DYRK1A 3997/4885CLK4 3560/4885CYP1A2 4581/4885 |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | DYRK1A 1886/4885CLK4 3746/4885CYP1A2 4131/4885 |
| US-20130023542-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | DYRK1A 1046/4885CLK4 2819/4885CYP1A2 4861/4885 |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | DYRK1A 1046/4885CLK4 2819/4885CYP1A2 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.